Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2 peptide vaccine + trastuzumab in HER2+ breast cancer
NCT03014076Phase 1Completed
- Sponsor
- Cancer Insight
- Start
- Jan 2008
- Primary completion
- Jan 2016
- Modality
- Peptides, Peptide-based Cancer Vaccines
01
Overview
Phase 1, open-label trial of GP2 peptide in breast cancer (2 arms), sponsored by Cancer Insight. Primary endpoint: Treatment-Related Adverse Events as Assessed by CTCAE v4.0 at 12 months. Started Jan 2008; status: completed.
02
Drugs
GP2 peptide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03014076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014076.